WeVote
Log In

Bill

Bill

A 5029

Relates to the substitution of brand name epinephrine auto-injectors with alternate epinephrine auto-injectors

2025 Regular Session Introduced by Jonathan Jacobson

Bill A 5029 allows pharmacists to substitute brand name epinephrine auto-injectors with alternatives, improving access to life-saving medication for allergy patients.

REFERRED TO HIGHER EDUCATION
0
WeVote Research Nonpartisan
Bill Summary · A 5029

Summary of Bill A 5029

Bill Information

  • Bill Number: A 5029
  • Title: Relates to the substitution of brand name epinephrine auto-injectors with alternate epinephrine auto-injectors
  • Status: Referred to Higher Education
  • Introduced: February 11, 2025
  • Classification: Bill

Purpose and Intent

Bill A 5029 aims to facilitate the substitution of brand name epinephrine auto-injectors with alternative epinephrine auto-injectors. This legislation is designed to improve access to life-saving medication for individuals at risk of severe allergic reactions (anaphylaxis) by allowing pharmacists to dispense alternative brands when the prescribed brand is not available.

Key Provisions

  • Substitution Authorization: The bill authorizes pharmacists to substitute prescribed brand name epinephrine auto-injectors with equivalent alternative products, ensuring that patients receive necessary medication without delay.
  • Standards for Substitution: The bill outlines specific criteria that alternative auto-injectors must meet to qualify for substitution, including efficacy and safety standards comparable to the brand name product.
  • Patient Notification: Pharmacists are required to inform patients about the substitution and provide information regarding the alternative product, including any differences in dosage or administration.
  • Insurance Coverage: The bill encourages insurance providers to cover both brand name and alternative epinephrine auto-injectors to ensure that patients are not financially burdened by the substitution.

Who Would Be Affected

  • Patients: Individuals who require epinephrine auto-injectors for severe allergic reactions will benefit from increased access to medication.
  • Pharmacists: Pharmacists will have the authority to substitute medications, which may require additional training or updates to pharmacy practices.
  • Healthcare Providers: Doctors and other healthcare providers will need to communicate effectively with patients regarding the availability and use of alternative auto-injectors.

Procedural Aspects

  • Current Status: As of February 11, 2025, the bill has been referred to the Higher Education Committee for further consideration.
  • Related Legislation: This bill is related to several prior-session bills (A 7219, A 1181, A 3981, A 6988) and has a companion bill in the Senate (S 1795), indicating ongoing legislative interest in this area.

Conclusion

Bill A 5029 represents a significant step towards improving access to essential medications for individuals at risk of anaphylaxis. By allowing for the substitution of epinephrine auto-injectors, the bill aims to enhance patient care and ensure that life-saving treatments are readily available. Further discussions and evaluations by the Higher Education Committee will determine the bill's future trajectory.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.